|Budget Amount *help
¥2,300,000 (Direct Cost: ¥2,300,000)
Fiscal Year 1996: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 1995: ¥1,300,000 (Direct Cost: ¥1,300,000)
Tumor angiogenesis is controlled by vascular endothelial growth factor, platelet-derived growth facter, and fibroblast growth factor. These growth factors involve a combination of events including the production of inhibitors, and angiogenic factors that have a chemotactic and mitogenic effect on endothelial cells.
Vascular endothelial growth factor (VEGF) is a heparin-binding growth factor that promotes angiogenesis in solid tumor, including brain tumors such as glioblastoma.
As an approach to the development for gene therapy of brain tumors, we have examined antisense VEGF gene expression in a variety of human glioma cells, and interrupted the VEGF/VEGF reseptor paracrine pathway.
T98G,U138MG,U87MG,PNET cells were transfected with EBV expression vector pCEP4 bearing an antisense VEGF cDNA.The stable transfectant cell and control cell clones were analyzed for growth in monolayr. The stable transfectant cells appeared phenotypically indistinguishable from normal cells and control cells. However, the growth rates of the stable transfectant cells differed markedly from the control cells.
Here, we show that antisence VEGF can be successfully used to control tumor growth and may provide the antiangiogenic gene therapy.